

Sheet 1 of 1		
Form PTO-1449 U.S. Department of Commerce Supplemental Information Disclosure Statement	DOCKET NO. 046483-6001US11(00853)	APPLN. NO. 14/996,953
	APPLICANT: Carl H. June, et al.	
	FILING DATE: January 15, 2016	GROUP: 1633

U.S. PATENT DOCUMENTS							
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if appropriate	
	7,402,431	07-22-2008	Michael Har-Noy				
FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	Subclass	Translation Yes/No /Abstract	
	WO 2005/044996	19 May 2005	PCT				
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, etc.)							
	Colombian Patent Application No. 15-80428 – Office Action issued December 23, 2015.						
	Colombian Patent Application No. - No. 13-137536 – Office Action issued November 23, 2015						
	Eurasian Patent Application No. 201390847 – Office Action issued February 14, 2016						
	U.S. Patent Application No. 13/992,622 – Final Office Action issued January 5, 2016						
	“Genetically Engineered Lymphocyte Therapy in Treating Patients with B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy” ClinicalTrials.gov Identifier NCT01029366; Retrieved from the internet on January 29, 2016. Found at https://www.clinicaltrials.gov/ct2/show/NCT01029366?term=NCT01029366&rank=1						
	“Pilot Study for Patients with Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma (CART-19)” ClinicalTrials.gov Identifier: NCT00891215; Retrieved from the internet on September 2, 2015. Found at http://web.archive.org/web/20090903002304/http://clinicaltrials.gov/ct2/show/NCT00891215						
	AppliChem product sheet for RPMI-1640, 2 pages, downloaded 12/28/2015						
	Milone, M. et al., Supplementary Materials and Methods, Mol Ther, Vol. 17, 2009, 7 pages						

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Examiner Signature: /Michael Burkhart/	Date Considered: 05/31/2016
--	---